Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01641029 · ClinicalTrials.gov registry record
Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis
A clinical trial, sponsored by Olive View-UCLA Education & Research Institute.
- Completed
- Registry status
- 720
- Enrollment target
NCT01641029 is a clinical trial that has completed, run by Olive View-UCLA Education & Research Institute. The registered enrollment target is 720 participants.
The verdict
NCT01641029 has completed, sponsored by Olive View-UCLA Education & Research Institute.
- COMPLETED
- Registry status
- 720 participants
- Enrollment target
Study Summary
Pyelonephritis is a serious infection that manifests with fever, back pain, nausea, and vomiting. In the U.S., it is estimated that there are 20 cases of pyelonephritis per 10,000 annually, with the highest incidence in young women. Escherichia coli (E. coli) causes over 80% of these infections. Over the last two decades, E. coli resistance has emerged to commonly prescribed antimicrobials, such as ampicillin and trimethoprim-sulfamethoxazole (TMP/SMX). Most recently, resistance to fluoroquinolones and strains producing extended-spectrum beta-lactamases (ESBL) have been observed. In order to better understand the evolution and current state of antibiotic resistance among E. coli urinary tract isolates so as to better inform treatment decisions, the investigators propose to conduct an investigation to: a) determine the prevalence of antimicrobial resistance among E. coli causing acute pyelonephritis in various patient groups, and specifically healthy community-dwellers with uncomplicated infections, b) determine the specific prevalence of fluoroquinolone-resistance and ESBL-producing E. coli, and c) determine potential risk factors for fluoroquinolone and ESBL-producing E. coli infections.
Interventions
- OTHER No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01641029
The ClinicalTrials.gov registry entry for NCT01641029 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 720 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Olive View-UCLA Education & Research Institute, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT01641029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01641029 about?
NCT01641029 is a clinical study titled "Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis". Pyelonephritis is a serious infection that manifests with fever, back pain, nausea, and vomiting. In the U.S., it is estimated that there are 20 cases of pyelonephritis per 10,000 annually, with the highest incidence in young women. Escherichia coli (E. coli) causes over 80% of these infections. Ove...
What is the current status of trial NCT01641029?
This trial is currently completed. The enrollment target is 720 participants. The study started on 2013-07. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01641029?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT01641029?
This trial is sponsored by Olive View-UCLA Education & Research Institute, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.